SITC 2024 Highlights Webinar-Webinar Recording

Video Transcription

Video Summary

In a recent ILSRC webinar, Dr. Jacob Sands discussed the Phase 3 trial (KiVy008) comparing the efficacy of Vibistolomab (TIGIT antibody) with Pembrolizumab plus chemotherapy against Atezolizumab plus chemotherapy in treating extensive-stage small cell lung cancer. The results were disappointing as they showed no overall survival benefit for the Vibistolomab-Pembrolizumab combination, with a numerical favor for the Atezolizumab arm. The trials indicated higher toxicity levels, prompting cessation of the study. Meanwhile, Dr. Melissa Johnson presented findings from ARC-10 focusing on the potential of anti-TIGIT Domvanilimab with Zimbrelumab in improving progression-free and overall survival in PD-L1 high non-small cell lung cancer patients, highlighting promising results pointing towards improved survival and lower risk of death. Furthermore, Alex Chen explored the use of AI in predicting immunotherapy responses through analyzing digital histopathology images, promoting deeper understandings of tumor microenvironment which could help refine treatment guidance. Lastly, Dr. Solange Peters shared insights from the PERLA study comparing Dostarlimab to Pembrolizumab, which showed similar efficacy and safety, but Dostarlimab indicated a numerical advantage in overall survival, suggesting further explorations.

Asset Subtitle

2024 SITC Highlights Webinar | English | 60 minutes

Meta Tag

Concept KEYVIBE-008

Concept ARC-10 Part 1

Concept PERLA Phase II Study

Concept Extensive-stage Small Cell Lung Cancer

Concept TIGIT Blockade

Keywords

ILSRC webinar

Phase 3 trial

Vibistolomab

Pembrolizumab

Atezolizumab

small cell lung cancer

Domvanilimab

Zimbrelumab

immunotherapy

KEYVIBE-008

ARC-10 Part 1

PERLA Phase II Study

Extensive-stage Small Cell Lung Cancer

TIGIT Blockade